Background: S-1+cisplatin (CDDP) is the standard treatment for advanced gastric cancer (AGC) in Japan and Korea. However, the usefulness of S-1 based chemotherapy for elderly patients is unclear. Therefore, we conducted a multicenter phase II study of S-1 monotherapy for AGC in elderly patients.
Materials And Methods: Chemotherapy-naïve patients aged over 75 years with AGC were enrolled. The starting dose of S-1 was determined on the basis of body surface area and modified according to the creatinine clearance value. S-1 was administered twice a day during a 4-week period followed by a 2-week rest period.
Results: Thirty-five patients were enrolled. The response rate (RR) was 14.3% and the median overall survival was 14.6 months. Grade 3 or more severe adverse events consisted of anaemia (3%), neutropaenia (3%), anorexia (3%), and fatigue (6%). There were no treatment-related deaths.
Conclusion: Our study indicates that S-1 monotherapy is safe and well tolerated in chemotherapy-naïve elderly patients with AGC, but exerts limited activity when given using a tailor-made dosing strategy based on renal function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1179/1973947813Y.0000000116 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Durable response from tegafur/gimeracil/oteracil (S-1) combined with fruquintinib and sintilimab as a third-line treatment for MSS metastatic colorectal cancer with a BRAF V600E mutation.
Front Oncol
December 2024
Department of Medical Oncology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Medical College, University of Guangzhou Traditional Chinese Medicine, Guangzhou, China.
Patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who fail first- and second-line treatments face significant challenges in third-line therapy, where monotherapies often yield poor outcomes and limited survival benefits. The prognosis is particularly poor for mCRC with the unique molecular subtype of BRAF V600E mutation. This report describes sustained benefits from a third-line treatment regimen (SFS) combining tegafur/gimeracil/oteracil (S-1), fruquintinib, and sintilimab in a patient with BRAF V600E-mutated MSS mCRC.
View Article and Find Full Text PDF[A Case of Pathological Complete Response after Nivolumab Therapy in Unresectable Advanced Gastric Cancer].
Gan To Kagaku Ryoho
December 2024
Dept. of Surgery, Nara Prefecture General Medical Center.
A 70-year-old man was admitted to a local hospital with epigastric pain and diagnosed with type-2 gastric cancer. Contrast-enhanced CT scan showed metastases in S3 and S8 of the liver, and the tumor was classified as type cT4aN2H1, cStage ⅣB. Nivolumab monotherapy was initiated after failure of treatment with S-1 plus oxaliplatin and ramucirumab.
View Article and Find Full Text PDFThe application of immunotherapy combined with taxanes in second‑line treatment of advanced HER2 negative gastric cancer.
Mol Clin Oncol
January 2025
Department of Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, P.R. China.
Human epidermal growth factor receptor-2 (HER2) negative advanced gastric cancer (GC) has a high global incidence and mortality rate with limited options for second-line treatment. Monotherapy is not effective and the combination of chemotherapy and immunotherapy has not yet been included in the guidelines. The present study aimed to explore a new treatment approach by conducting a single-center, retrospective, observational real-world study.
View Article and Find Full Text PDFEfficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.
J Gastroenterol
November 2024
Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Background: S-1 monotherapy had previously been widely used as a second-line treatment for pancreatic cancer (PC) after gemcitabine-based chemotherapy mainly in Japan. Based on the results of the NAPOLI-1 trial, the recommended second-line therapy is now liposomal irinotecan plus fluorouracil/folinic acid (nal-IRI + 5-FU/LV). However, there have been no studies comparing nal-IRI + 5-FU/LV therapy with S-1 monotherapy.
View Article and Find Full Text PDFRecent efficacy and long-term survival of polysaccharide combined with gemcitabine and S-1 in pancreatic cancer.
World J Clin Oncol
November 2024
Zhejiang Cancer Hospital, Hangzhou 310000, Zhejiang Province, China.
Article Synopsis
- Pancreatic cancer is aggressive and often spreads quickly; APS, a traditional Chinese medicine, shows promise in treating various malignant tumors.
- A recent study examined the effectiveness of combining APS with the GS chemotherapy regimen in 97 pancreatic cancer patients, comparing those who received combination therapy to those who solely received GS.
- Results showed the combined APS and GS therapy led to better response rates, improved immune function, and fewer adverse side effects compared to GS alone, indicating a potential benefits for long-term survival.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!